Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961516 · ClinicalTrials.gov registry record
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 34
- Enrollment target
NCT03961516: Completed study, sponsored by University Hospitals Cleveland Medical Center.
NCT03961516 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03961516 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.
Primary Outcome
Difference between blood glucose and CGM result will be calculated for each time point (0min, 30min, 60min, 90min, 120min).
Interventions
- DEVICE Frequently Sampled Oral Glucose Tolerance Test and CGM
- RADIATION MRI Pancreas and Liver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-08-30 |
What the finished NCT03961516 record still lists
NCT03961516 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Frequently Sampled Oral Glucose Tolerance Test and CGM is the first listed.
NCT03961516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03961516 about?
NCT03961516 is a clinical study titled "Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis". The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently ...
What is the current status of trial NCT03961516?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2019-05-01. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03961516?
The interventions under investigation include: Frequently Sampled Oral Glucose Tolerance Test and CGM (DEVICE), MRI Pancreas and Liver (RADIATION).
Who is sponsoring clinical trial NCT03961516?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI